Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference
Generation Bio (Nasdaq: GBIO), a biotechnology company focused on T cell-driven autoimmune diseases, has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Generation Bio (Nasdaq: GBIO), a biotechnology company focused on T cell-driven autoimmune diseases, has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference.
The company's President and CEO, Geoff McDonough, M.D., will engage in a fireside chat scheduled for Wednesday, April 9th at 12:45 p.m. ET. Investors and interested parties can access the live webcast through the investor section at investors.generationbio.com, where a replay will remain available for 30 days after the event.
Details
News Market Reaction – GBIO
The recorded move for GBIO in the trading session of this news was +0.57%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9th at 12:45 p.m. ET.
A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.
About Generation Bio
Generation Bio is a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases. The company is developing redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells, which erroneously recognize and attack the body’s own tissues, causing autoimmune diseases. Generation Bio’s innovative approach leverages cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) to T cells. This combination of selective delivery and an intracellular, genetically precise mechanism of target engagement could unlock a series of high-value, historically undruggable disease-driving genes in autoimmunity.
For more information, please visit www.generationbio.com.
Investors and Media Contact
Maren Killackey
Generation Bio
mkillackey@generationbio.com
857-371-4638
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.